ArriVent BioPharma (AVBP) investor relations material

Executive summary

• Focused on developing and commercializing differentiated oncology medicines, with lead candidate firmonertinib in pivotal Phase 3 trials for EGFR-mutant NSCLC and ARR-217 in Phase 1 for solid tumors; topline data for firmonertinib expected in 2H 2026.

• Progressed ARR-217 (CDH17-targeted ADC) to Phase 1b dose optimization for gastrointestinal malignancies.

• ARR-002 (dual-target MUC16/NaPi2b ADC) set for first patient dosing in Q3 2026, with exclusive Greater China licensing agreement signed.

• No product revenue generated to date; operations funded by equity offerings and collaborations.

• Received FDA Breakthrough Therapy and Orphan Drug Designations for firmonertinib.

Financial highlights

• Net loss was $49.9 million for Q2 2026, compared to $31.4 million in Q2 2025; net loss for the six months ended June 30, 2026 was $93.2 million, compared to $95.8 million in the prior year period.

• Operating expenses for Q2 2026 were $52.7 million, up from $33.6 million in Q2 2025, driven by increased R&D and G&A costs.

• Research and development expenses were $80.0 million for the six months ended June 30, 2026, down from $89.0 million year-over-year; G&A expenses increased to $18.8 million from $11.4 million.

• Interest and investment income rose to $2.8 million in Q2 2026 from $2.2 million in Q2 2025.

• Cash, cash equivalents, and short-term investments totaled $373.1 million as of June 30, 2026, expected to fund operations into 2028.

Outlook and guidance

• Existing cash and investments expected to fund operations for at least 12 months from the financial statement issuance date and into 2028.

• Anticipates continued operating losses as clinical and preclinical programs advance; expects increased expenses for R&D, regulatory, and commercialization activities.

• Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected in 2H 2026.

• Initial Phase 1 data for ARR-217 to be presented at a future medical conference.

• First patient dosing for ARR-002 in Phase 1 trial anticipated in Q3 2026.